论文部分内容阅读
近15年来,儿童急性淋巴细胞白血病(简称急淋)的疗效明显提高。由于有效化学治疗药物增多,治疗与用药量的改进,中枢神经系统的予防,缓解期的积极治疗,支持疗法的改进等,近来报导已有50%的儿童急淋无病生存五年以上。作者对137例儿童急淋患者(其中分类不明型10例),用长春新碱+强的松作为诱导缓解的治疗方案,部份病例加红比霉素或阿霉素,完全缓解率为94%(129/137)。7例诱导缓解失败病例的分析,发现分类不明型白血病及年龄是诱导缓解的决定因素,分类不明者缓解率低;小于2岁与大于9岁儿童诱导缓解失败率高于2～
In the past 15 years, the curative effect of childhood acute lymphoblastic leukemia (abbreviated as acute leukemia) has increased significantly. Due to the increase of effective chemotherapeutic drugs, improvement of treatment and dosage, prevention of central nervous system, active treatment during remission, improvement of supportive therapy, recently reported that 50% of children have survived leaching and disease-free survival for more than five years. The author of 137 cases of acute leukemia in children (including 10 cases of unknown classification), with vincristine + prednisone as a remission treatment program, some cases of red bromide or adriamycin, complete remission rate of 94 % (129/137). Analysis of 7 cases of failed remission induction found that unclassified leukemia and age were the determinants of induction of remission, and the remission rate was low in unclassified patients; the failure rate of induction remission in children younger than 2 years and older than 9 years was higher than 2